Apellis Pharmaceuticals Stock Cycle Indicators Hilbert Transform Phasor Components

APLS Stock

USD 18.94 0.55 2.99%

This cycle indicators tool runs Hilbert Transform Phasor Components indicator and companion studies for Apellis Pharmaceuticals. Signals here center on cycle timing and phase shifts in Apellis Pharmaceuticals price series alongside volatility and performance references.

Symbol

Indicator

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. Apellis Pharmaceuticals Hilbert Transform - Phasor Components indicator is used to generate in-phase and quadrature components of Apellis Pharmaceuticals price series in order to analyze variations of the instantaneous phase and amplitude.

Apellis Pharmaceuticals Technical Analysis Modules

Most technical analysis of Apellis Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Apellis from various momentum indicators to cycle indicators. When you analyze Apellis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

	Cycle Indicators
	Math Operators
	Math Transform
	Momentum Indicators
	Overlap Studies
	Pattern Recognition
	Price Transform
	Statistic Functions
	Volatility Indicators
	Volume Indicators

Stock Overview, Methodology & Data Sources

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. This overview emphasizes how Apellis Pharmaceuticals compares to peers on valuation quality and operating consistency. Current metrics include P/B of 6.54, profit margin of 2.23%. Apellis Pharmaceuticals has a market cap of 2.42 B, ROE of 7.48%.

Methodology

Unless otherwise specified, financial data for Apellis Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Apellis (USA Stocks:APLS) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Apellis Pharmaceuticals is covered by 22 analysts. 11 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Oppenheimer & Co., RBC Capital Markets, J.P. Morgan, Wells Fargo Securities, Guggenheim Securities, Deutsche Bank, Raymond James, Citigroup, HSBC Global Research, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board

Learn to be your own money manager

Tracking Apellis Pharmaceuticals inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.

Did you try this?

Run Share Portfolio Now

Share Portfolio

Track or share privately all of your investments from the convenience of any device

All Next

Launch Module

Apellis Pharmaceuticals pair trading

Pair trading with Apellis Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.

Apellis Pharmaceuticals Pair Trading

Apellis Pharmaceuticals Pair Trading Analysis

The effectiveness of tax-loss harvesting on Apellis Pharmaceuticals depends on finding a suitable replacement asset. Instruments with correlation above 0.9 to Apellis Pharmaceuticals typically provide adequate market exposure during the required holding period.

Interpreting the correlation table for Apellis Pharmaceuticals: readings above 0.8 indicate strongly correlated pairs with minimal diversification benefit, while readings between -0.2 and +0.2 around Apellis Pharmaceuticals suggest near-independence and genuine portfolio diversification value.

Use Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals to review hedging context. The view can be extended across sectors or other related groups.

Pair Correlation Correlation Matching

Additional Tools for Apellis Stock Analysis

	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC